CSA Medical, a manufacturer of CryoSpray Ablation System, has appointed William Floyd as president, CEO and member of the board of directors.
Floyd brings more than 20 years of medical device experience, including market development roles commercialising disposables, implants, capital equipment and monitoring systems
Prior to joining CSA Medical, Bill served as vice president of US Sales for Covidien following the sale of Aspect Medical Systems to Covidien in 2009 and was executive vice president of worldwide Sales and Marketing at Aspect Medical Systems previously.
Earlier in his career, Bill spent five years serving as vice president of Marketing at Boston Scientific, where he developed and executed the urology division’s five year strategic plan focused on growth and diversification.
Previously, Bill held numerous senior sales and marketing positions with Johnson & Johnson (Codman & Shurtleff) and Procter and Gamble.
Floyd said CSA Medical’s spray cryotherapy is a new technology that holds promise to stop disease processes and dramatically improve the quality of life forms of patients.
"I look forward to working with our team to bring the benefits of this technology to more patients across the globe as we expand our customer and procedure base," Floyd said.
CSA Medical develops and manufactures a proprietary therapeutic interventional treatment platform, the CryoSpray Ablation System, that delivers therapeutic doses of a cryogen to flash freeze and destroy diseased tissue inside the body.